Welcome to our dedicated page for Gritstone bio news (Ticker: GRTS), a resource for investors and traders seeking the latest updates and insights on Gritstone bio stock.
Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology leader developing novel immunotherapies and vaccines for cancer and infectious diseases. This dedicated news hub provides investors and researchers with essential updates on the company’s pioneering work in neoantigen-targeting platforms and self-amplifying mRNA technology.
Access real-time announcements including clinical trial results, regulatory milestones, and strategic collaborations. Our curated collection features:
• Clinical development updates for GRANITE and SLATE vaccine programs
• Technology innovations in AI-driven EDGE platform and samRNA vectors
• Partnership announcements with leading research institutions
• Peer-reviewed data publications and conference presentations
Bookmark this page for streamlined tracking of Gritstone bio’s progress in advancing personalized cancer vaccines and next-generation infectious disease solutions. All content is sourced directly from company filings and verified industry channels.
Gritstone Oncology (Nasdaq: GRTS) announced that Dr. Andrew Allen will present a company overview at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET.
The presentation will be available via a webcast on the company's website, with an archived replay accessible for 30 days post-event. Gritstone focuses on developing advanced immunotherapies for cancer and infectious diseases using its proprietary Gritstone EDGE™ platform. Key programs include GRANITE and SLATE for oncology, alongside initiatives for COVID-19 and HIV vaccines.
Gilead Sciences (Nasdaq: GILD) and Gritstone Oncology (Nasdaq: GRTS) have announced a collaboration to develop a vaccine-based immunotherapy aimed at curing human immunodeficiency virus (HIV) infection. The partnership will utilize Gritstone's prime-boost vaccine platform, combining self-amplifying mRNA and adenoviral vectors with antigens from Gilead. Gilead will initially invest $60 million, including a $30 million cash payment and a $30 million equity investment, and has the option for further funding up to $725 million based on clinical milestones.
Gritstone Oncology has entered a nonexclusive agreement with Genevant Sciences to access its lipid nanoparticle (LNP) technology for the development of self-amplifying RNA vaccines targeting COVID-19. This collaboration aims to enhance the vaccine's effectiveness against emerging virus strains. Gritstone anticipates initiating a Phase 1 clinical trial in the first quarter of 2021, supported by a potential $192 million in milestone payments to Genevant. The partnership builds upon their existing relationship and leverages Gritstone's innovative cancer immunotherapy platforms.
Gritstone Oncology (Nasdaq: GRTS) has announced progress on its second-generation vaccine against SARS-CoV-2, targeting prolonged protection and efficacy against Spike variants. A Phase 1 clinical trial is set to begin, supported by the National Institute of Allergy and Infectious Diseases (NIAID) and the Bill & Melinda Gates Foundation. The vaccine will leverage validated SARS-CoV-2 epitopes from the La Jolla Institute for Immunology and employ self-amplifying mRNA and adenoviral vectors. Gritstone aims for improved T cell and antibody responses compared to existing vaccines.
Gritstone Oncology (Nasdaq: GRTS) announced that Andrew Allen, M.D., Ph.D., will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 5:20 p.m. ET. The event will be available via live webcast on the company's website, with an archived replay accessible for 30 days. Gritstone focuses on developing next-generation cancer immunotherapies using proprietary technology that identifies tumor-specific neoantigens. Their two key products include GRANITE and SLATE, both currently in clinical evaluation.
Gritstone Oncology (Nasdaq: GRTS) has announced the successful closure of a $110 million private investment in public equity (PIPE) financing, alongside an additional $15 million PIPE financing, totaling $125 million in gross proceeds. The share price was set at $3.71, with strong backing from reputable institutional investors. The latest financing is expected to close on December 30, 2020, pending customary conditions. Gritstone, focused on cancer immunotherapies, plans to register the resale of shares with the SEC.
Gritstone Oncology, Inc. (Nasdaq: GRTS) has announced a successful PIPE financing to raise $110 million by selling shares at $3.34 each. This financing, led by Redmile Group and others, is expected to close on December 28, 2020. The funds will support the clinical development of its leading cancer immunotherapies, GRANITE and SLATE, and enhance its Gritstone EDGE™ technology. The company plans to register the shares with the SEC following this offering, which is compliant with Nasdaq rules.
Gritstone Oncology reported third-quarter 2020 financial results, showing a net loss of $26.1 million, a slight improvement from $27.5 million in Q3 2019. Collaboration revenue decreased to $0.8 million from $1.0 million year-over-year. R&D expenses fell to $22.1 million from $24.9 million, attributed to reduced milestone payments, while general and administrative costs rose to $5.0 million. The company is advancing its immunotherapy programs, GRANITE and SLATE, and has initiated Phase 2 expansion cohorts for both as it aims to enhance clinical efficacy against various cancers.
Gritstone Oncology (Nasdaq: GRTS) has commenced dosing patients in the Phase 2 cohorts of its Phase 1/2 clinical studies for GRANITE and SLATE, innovative neoantigen-based immunotherapies. This advancement follows promising Phase 1 data showing potential immune response in metastatic colorectal and gastro-esophageal cancers. Fast Track designation from the FDA was granted for GRANITE targeting microsatellite stable colorectal cancer. These trials intend to evaluate immunotherapy's effectiveness in historically cold tumors, offering hope for improved patient outcomes.
Gritstone Oncology (Nasdaq: GRTS) announced that Andrew Allen, M.D., Ph.D., will present a company overview at the Cantor Virtual Global Healthcare Conference on September 17, 2020, at 8:00 a.m. ET. Gritstone is focused on developing next-generation cancer immunotherapies against multiple cancer types. Its proprietary Gritstone EDGE platform and individualized neoantigen-based immunotherapy, GRANITE, are key components of its strategy. The live webcast will be accessible on their website, with an archived replay available for 30 days post-event.
